Financial Statements of the Parent Company Sartorius Stedim Biotech S.A. as of December 31, 2021

Financial Statements of the Parent Company

Sartorius Stedim Biotech S.A. is the parent company of the Group. The company is a mixed holding Company. The company from now on is managing investments of the Group and real estates for the French Companies.

In 2021, sales revenue generated at Sartorius Stedim Biotech S.A. was €K 2,110 compared to €K 1,877 in 2020. The operating profit is €K -8,939 versus €K -4,623 K in 2020. The net financing income totalled €K 123,045 versus €K 85,043 in 2020.

The net profit for 2021 is €K 115 521 compared to €K 81,227 in 2020.

Appropriation of the Net Profit

The ASM will suggest to appropriate the net profit of €115,521,400 for the reporting year of 2021 as follows:

- The following amount is to be added to this balance: Year-earlier profit carried forward: €75,362,590
- This would yield a distributable profit of €190,883,990
- Total amount of dividends to be disbursed to shareholders: €116,142,805 excluding treasury shares
- Balance resulting from disbursement: €74,741,185

The remaining amount of €74,741,185 is to be carried out to the next year.

Dividends of the last three financial years (information updated as of 1st January 2021)

The table below lists the amount of the dividend per share distributed, since 2018, as well as the applicable tax provisions.

Exercise	Dividend[1]	Amount eligible for the 40% abatement	Amount not eligible for the 40% abatement	Dividend per shares[1]
Dec. 31, 2020	62,681,786	62,681,786	0	0.68 €
Dec. 31, 2019	31,341,265	31,341,265	0	0.34 €
Dec. 31, 2018	52,540,761	31,341,265	0	0.57 €

1 Prior deduction of social contribution on the dividend paid to physical person.

Proposition of dividend for the 2021 financial year

The Board of Directors has decided to propose on the 24th of March 2022 Annual Shareholders' Meeting a net dividend of €1.26 per share for the 2021 financial year in comparison with €0.68 for 2020.

The dividends are distributed to the shareholders based on the proportion of the capital they hold.

The dividend will be paid on 31 March 2022.

Dividend distribution policy

The company has a policy of dividend distribution linked to the Group's profit over the financial year concerned on the one hand and to the Group's predictable evolution and profitability on the other hand.

On the 24th of March 2021, the Shareholders' Meeting voted a net dividend of €0.68 per share. The payment of the dividend was done on March 31, 2021.

Dividends and interim dividends paid and unclaimed are prescribed in favour of the State five years after their date of payment (article 2277 of the Civil Code).

Elements likely to have an impact in the event of a public offer

According to article L. 225-100-3 of the French Commercial Code, an element is likely to have an impact in the event of a public offer: the first shareholder of Sartorius Stedim Biotech S.A. holds a significant percentage of its capital and voting rights.

Sartorius Stedim Biotech S.A. Share Capital

Share Capital as of December 31, 2021

As of 31 December 2021, the share capital amounts to eighteen million four hundred and thirty-six thousand thirty-eight euros (€18,436,038). It is divided into twenty-two million one hundred and eighty thousand one hundred and ninety (92,180,190) shares worth twenty cents euros (€0.20) each, all fully subscribed and paid up (Heading I, Article 6 of the bylaws), all of which are entitled to the dividend for the financial year 2020, with the exception of shares held by the Company.

Date	Nature of the transaction	Share par value	Share capital increase	Share premium	Number of new shares	Number of shares after the transaction	Share capital after the transaction
Year 2015	Exercise of share subscription options	1.00	8,000.0	174,880.0	8,000.0	15,367,238	15,367,238.0
Year 2016	Reduction of Capital: Cancellation of Treasury Shares	1.00	−1,642,095.0		−1,642,095.0	13,725,143	13,725,143.0
Year 2016	Increase of Capital: new actions created	1.00	1,638,222.0		1,638,222.0	15,363,365	15,363,365.0
Year 2016	Increase of Capital: nominal value change	0.20	3,072,673.0		3,072,673.0	92,180,190	18,436,038.0
Year 2017						92,180,190	18,436,038.0
Year 2018						92,180,190	18,436,038.0
Year 2019						92,180,190	18,436,038.0
Year 2020						92,180,190	18,436,038.0
Year 2021						92,180,190	18,436,038.0

Sartorius Stedim Biotech S.A. Shareholdings as of December 31, 2021

Situation of Sartorius Stedim Biotech S.A. Shareholdings

Shareholders	Shares	Voting rights
More than 50%	Sartorius AG	Sartorius AG
More than 10% but less than 50%	None	None
More than 5% but less than 10%	None	None

Over the past three years, the ownership of Sartorius Stedim Biotech S.A. share capital has been distributed as follows:

	December 31, 2019			December 31, 2020			December 31, 2021		
Shareholders	Number of shares	% of share capital	% of voting rights	Number of shares	% of share capital	% of voting rights	Number of shares	% of share capital	% of voting rights
Sartorius AG	68,450,400	74.3%	84.5%	68,044,513	73.8%	84.3%	68,044,513	73.8%	84.8%
Single voting rights									
Double voting rights	68,450,400	74.3%	84.5%	68,044,513	73.8%	84.3%	68,044,513	73.8%	84.8%
Single voting rights									
Double voting rights	0	0.0%	0.0%						
Total Sartorius Group	68,450,400	74.3%	84.5%	68,044,513	73.8%	84.3%	68,044,513	73.8%	84.8%
Treasury shares									
Personnel and other shareholders									
General public	23,729,790	25.7%	15.5%	24,135,677	26.2%	15.7%	24,135,677	26.2%	15.2%
Single voting rights	22,439,112	24.3%	13.9%	22,844,999	24.8%	14.1%	23,833,997	25.9%	14.8%
Double voting rights	1,290,678	1.4%	1.6%	1,290,678	1.4%	1.6%	301,680	0.3%	0.4%
Total shares	92,180,190	100.0%	100.0%	92,180,190	100.0%	100.0%	92,180,190	100.0%	100.0%

Legal Disclosure of Thresholds Crossed

No legal disclosure of thresholds crossed has been registered during the fiscal year under study.

	Shares	% Issued Capital	Voting rights	% Voting rights
Sartorius AG	68,044,513	73.8	136,089,026	84.8
Total Sartorius AG	68,044,513	73.8	136,089,026	84.8

Control of the Company as of December 31, 2021

Sartorius AG holds, directly or indirectly, 73.8% of the share capital and 84.8% of the outstanding voting rights. Treasury shares are without voting rights.

Staff Shareholdings

None

Treasury Shares Held by Sartorius Stedim Biotech S.A.

None

Unpaid Capital

None

Authorized but Unissued Capital

None

Securities Not Representative of the Share Capital

None

Authority granted by the Annual Shareholders' Meeting to the Board of Directors still valid.

Delegation granted for increase in Capital by the Shareholder's Meeting to the Board of Directors

Object - Duration	Limit	Use in 2020
Ability to issue shares and/or securities giving access to the share capital of the company and/or securities giving the right to the allotment of the debt instruments, with preferential subscription rights of the shareholders. (EGM 06/24/2020 – Resolution n°11) Granted for a period of 26 months as from 24/06/2020	The limit is €4,000,000 corresponding to the maximum nominal amount of the increase of the share capital and to the maximal nominal amount of the debt instruments and €500,000,000 on the maximum overall limit of the maximum nominal amount of the debt instruments. It being specified that the limits of the nominal amount of the capital increases and debt instrument, with or without preferential subscription rights of the shareholders, set from the twelfth (12th) to the seventeenth (17th) resolutions submitted to this Shareholders' Meeting shall be deducted from this overall limit	None
Ability to issue shares and/or securities giving access to the share capital of the company and/or securities giving the right of the allotment of debt instruments, without preferential subscription rights of the shareholders – through public offerings,other than those referred to in the Article L. 411-2 of the French Monetary and Financial Code. (EGM 06/24/2020 – Resolution n° 12) Granted for a period of 26 months as from 24/06/2020	The limit is deducted on the overall limit of €4,000,000 (increase of the share capital) and on the overall limit of €500,000,000 (debt instruments).	None
Ability to issue shares and/or securities giving access to the share capital of the Company and/or securities giving the right to the allotment of debt instruments, without preferential subscription rights of the shareholders - through public offers addressed exclusively to qualified investors or to a restricted circle of investors as defined in the article L. 411-2 of the French Monetary and Financial Code. (EGM 06/24/2020 – Resolution n° 13) Granted for a period of 26 months as from 24/06/2020	The limit is deducted on the overall limit of €4,000,000 (increase of the share capital) and on the overall limit of €500,000,000 (debt instruments).	None
Ability to increase the number of shares and/or securities giving access to the share capital of the Company to be issued in the event of a share capital increase with or without preferential subscription rights of the shareholders. (EGM 06/24/2020 – Resolution n° 14) Granted for a period of 26 months as from 24/06/2020	The limit amount 15% of initial issue of shares, pursuant to the resolution n°11 to 13 described above.	None
Ability to issue shares and/or securities giving access to the share capital of the Company, as consideration for securities tendered through public exchange offers initiated by the Company, without preferential subscription right of the shareholders.(EGM 06/24/2020 – Resolution n° 15) Granted for a period of 26 months as from 24/06/2020	The limit is deducted on the overall limit of 10% of the share capital of the Company at the moment of the capital increase (increase of the share capital) and on the overall limit of €500,000,000 (debt instruments).	None
Ability to increase the share capital through the capitalization of reserves, earnings or premiums or any other sum upon which capitalization would be permitted. (EGM 06/24/2020 – Resolution n° 16)	The limit is €4,000,000 (corresponding to the maximum nominal amount of the increase of the share capital); It is a independent limit.	None

Granted for a period of 26 months as from 24/06/2020		
Ability to issue shares and/or securities giving access to the share capital giving the right to the allotment of debt instruments, without preferential subscription rights of the shareholders and reserved for members of saving plans. (EGM 06/24/2020 – Resolution n° 17)	The limit is €4,000,000 corresponding to the maximum nominal amount of the increase of the share capital; it is an independent limit.	None
Granted for a period of 26 months as from 24/06/2020		
Ability to reduce the capital by cancelling shares acquired under buyback program (EGM 06/24/2020 - Resolution n°18)	The limit is of 10% of the capital of the Company and by period of 24 months.	None
Granted for a period of 18 months as from 24/06/2020		
Ability to grant free new or existing shares to the benefit of employees or corporate officers (EGM 06/24/2020 - Resolution N°19)	The limit amount of 10% of the Company's share capital calculated on the attribution date	None
Granted for a period of 38 months as from 24/06/2020.		

Other Securities Giving Access to the Share Capital

None

Stock Options

None

Share Capital Dilution

None

Share Subscription Options Granted to Each Senior Executive of the Company and Options Exercised by Them in Fiscal 2021

None

Share Subscription Options Granted to the Ten Top Non-senior Executive Beneficiaries and Options Exercised by Them in the 2021 Fiscal Year

None

Options Exercised During the Fiscal Year

All options have been exercised in 2015. The stock option plans are now expired.

in €	2020	2019	2018	2017	2016
Dividend per share for the fiscal year	0.68	0.34	0.57	0.46	0.42
Number of shares	92,180,190	92,180,190	92,180,190	92,180,190	92,180,190
Dividend corrected per share[1]	0.68	0.34	0.57	0.46	0.42

1 Compared to the number of shares as of December 31, 2017

Share Subscription Plan

The stock option plans are detailed in the tables above. The authority delegated to the Board of Directors for setting up a new plan has recently expired. The Board of Directors no longer has any such delegated authority to set up any new plan.

Share Subscription Warrants

Sartorius Stedim Biotech S.A. has not issued any share subscription warrants.

Pledging of Shares

No Sartorius Stedim Biotech S.A. shares were pledged.

Pledging of Assets

None

Senior Executives

Information on Sartorius Stedim Biotech S.A. senior executives and a list of the positions they hold or have held over the past five years are included in the Corporate Governance report.

Directors' Fees

Directors' fees are calculated on an annual basis. The method of calculating these fees remains the same. It is as follows.

The directors receive directors' meeting attendance fees whose amount and allocation are established by the Board of Directors in consideration of the limits set by the ASM:

- Each Director receives a fixed remuneration of €35,000 per year, to be paid after the annual financial statements have been adopted by the Annual Shareholders' Meeting and which is due for payment after the Annual Shareholders' Meeting. The chairman of the Board receives twice this amount. Furthermore, members of the Board receive an attendance fee of €1,200 per meeting and reimbursement of their expenses in addition to the annual remuneration.

- For their membership to the Audit Committee, each Director receives a lump-sum amount of €6,000 per full year of membership in addition to the attendance fee of €1,200. If they chair the

committee of the Audit Committee, instead of this, they receive a lump-sum amount of €12,000 per full year that they hold the chairperson in addition to the attendance fee.

- For their membership to the Remunerations & Nominations Committee, each Director receives a lump-sum amount of €4,000 per full year of membership in addition to the attendance fee of €1,200. Insofar as they hold the chair of the Remunerations & Nominations Committee, instead of this, they receive a lump-sum amount of €8,000 per full year that they hold the chairperson in addition to the attendance fee.

The remuneration for the activities on any committee is due together with the remuneration under

- the terms of previous Subsection hereof.

- Any value-added tax is reimbursed by the corporation, insofar as the members of the Board are entitled to invoice the corporation separately for the value-added tax and they exercise this right.

- All these resolutions will not be applied to the Directors that got an executive top management activity at the group level, as well as for the Director(s) representing the employees. In this context, the executive corporate officers, as well as the Director(s) representing the employees will not receive any remuneration for their membership.

A total of €317,400 has been provisioned in directors' fees for 2021 (payment en 2022).

Compensation of the Executive Management Team

		Base | fixed salaries € in K	Annual incentive € in K	Long Term Incentive € in K	Other	Stock options € in K	Departure Indemnity € in K	Directors' meeting attendance fees € in K
Total 2020	1,776.0	451.5	273.0	1,044.0	7.5	0.0	0.0	0.0
Total 2021	2,002.5	500.0	360.0	1,112.5	30.0	0.0	0.0	0.0
Joachim Kreuzburg[1] 2020	1,776.0	451.5	273.0	1,044.0	7.5	0.0	0.0	0.0
Joachim Kreuzburg[1] 2021	2,002.5	500.0	360.0	1,112.5	30.0	0.0	0.0	0.0

1 For more details please refer to the Chapter Corporate Governance on pages 71 to 102.

Independent Auditors

The independent auditors for Sartorius Stedim Biotech S.A. are:

- KPMG S.A., represented by Nicolas Blasquez.

- Deloitte & Associés, represented by Christophe Perrau.

Payment Terms for Trade Payables & Receivables

	Article D. 441-1st : Invoices received but not paid at the date of the end of the exercicze whose term has expired						Article D. 441-2nd: Invoices sent but not paid at the date of the end of the exercize whose term has expired					
	0 day (indicative)	1 à 30 days	31 at 60 days	61 at 90 days	91 days and after	Total	0 day (indicative)	1 à 30 days	31 at 60 days	61 at 90 days	91 days and after	Total
(A) Repartition of late payment												
Number of concerned invoices	7	0	0	0	11	18	1	1	0	0	0	2
Total Amount of concerned invoices (Including all taxes)	110,705	0	0	0	31,507	142,212	-123,735	-79,271	0	0	0	-203,006
Percentage of Total amount of purchases including taxes for the exercize	1%	0%	0%	0%	0%	1%						
Percentage of sales including taxes for the exercize							5%	3%				8%
(B) Invoices excluded from (A) relating to disputed and and contentious Receivables non recorded												
Number of invoices excluded	0					0	0					0
Total amount of excluded invoices including taxes	0					0	0					0
(C) Reference payment terms used (Contractual or statutory period - article L. 441-6 or article L. 441-3 of Commerce Code)												
Payment terms used for the payment term calculation		Contractual time limit:			30 days			Contractual time limit:			30 days	
		Legal time limit:						Legal time limit:				

Five-Year Financial Results of the Parent Company
Sartorius Stedim Biotech S.A.

€ in K	2017	2018	2019	2020	2021
Share capital at end of period					
Share capital (capital stock)	18,436	18,436	18,436	18,436	18,436
Number of shares outstanding	92,180,190	92,180,190	92,180,190	92,180,190	92,180,190
Transactions and financial performance					
Sales revenue (excl. VAT)	2,198	1,999	2,116	1,876	2,110
Profit before tax, employee profit sharing plan, amortization, depreciation and provision expenses (and reversals)	55,840	54,135	57,230	81,367	115,005
Income tax	5,552	3,316	−443	−745	−1,416
Contribution to employee profit-sharing plan	0	0	0	0	0
Net profit	49,463	49,521	56,834	81,227	115,521
Dividends paid or proposal of dividend	38,713	42,403	52,541	31,341	62,683
Earnings per share					
EPS after tax and employee profit-sharing, but before amortization, depreciation and provision expenses	0.55	0.55	0.63	0.89	1.26
EPS after tax and employee profit-sharing, amortization, depreciation and provision expenses	0.54	0.54	0.62	0.88	1.25
Dividend per share	0.42	0.46	0.57	0.34	0.68
Personnel					
Workforce size	0	0	0	0	0
Personnel costs	0	0	0	0	0
Social security costs	0	0	0	0	0